



Atty Docket No.: JHV-050.01

Inventor: Tzyy-Chouu Wu *et al.*

Application No.: 10/555,669-Conf. #9879

Filing Date: May 5, 2004

Title: ANTI-CANCER DNA VACCINE EMPLOYING PLASMIDS ENCODING SIGNAL
SEQUENCE, MUTANT ONCO-PROTEIN ANTIGEN, AND HEAT SHOCK PROTEIN

Documents Filed:

Response to Notification of Missing Requirements (2 pages in dupl.)
Copy of Notification of Missing Requirements (3 pages)
Petition for Four Month Extension of Time Under 37 CFR 1.136(a) (1 page in dupl.)
Paper copy of Sequence Listing (17 pages)
CRF diskette of Sequence Listing (1 disk)
Statement to Support Sequence Listing submission (1 page)
Preliminary Amendment (3 pages)
Executed Declaration (1 page)
Executed Powers of Attorney (2 pages)
Notification of Change of Attorney Docket Number (1 page)

Via: First Class Mail

Sender's Initials: JYA/dmn

RECEIVED

MAR 29 2007

PATENT DEPT.
DOCKETING

IAP6 Rec'd PCT/PTO 22 MAR 2007

Atty Docket No.: JHV-050.01

Inventor: Tzyy-Chouu Wu *et al.*

Application No.: 10/555,669-Conf. #9879

Filing Date: May 5, 2004

Title: ANTI-CANCER DNA VACCINE EMPLOYING PLASMIDS ENCODING SIGNAL
SEQUENCE, MUTANT ONCO-PROTEIN ANTIGEN, AND HEAT SHOCK PROTEIN

Documents Filed:

Response to Notification of Missing Requirements (2 pages in dupl.)
Copy of Notification of Missing Requirements (3 pages)
Petition for Four Month Extension of Time Under 37 CFR 1.136(a) (1 page in dupl.)
Paper copy of Sequence Listing (17 pages)
CRF diskette of Sequence Listing (1 disk)
Statement to Support Sequence Listing submission (1 page)
Preliminary Amendment (3 pages)
Executed Declaration (1 page)
Executed Powers of Attorney (2 pages)
Notification of Change of Attorney Docket Number (1 page)

Via: First Class Mail

Sender's Initials: JYA/dmn

Date: March 19, 2007

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Wu, Tzyy-Chou et al.

Application No: 10/555,669

International Filing Date: May 5, 2004

For: ANTI-CANCER DNA VACCINE
EMPLOYING PLASMIDS ENCODING
SIGNAL SEQUENCE, MUTANT ONCO-
PROTEIN ANTIGEN, AND HEAT
SHOCK PROTEIN

Art Unit: *To be Determined*

Confirmation No.: 9879

Examiner: *To be Determined*

Docket No. JHV-050.01

CERTIFICATE OF FIRST CLASS MAILING

I hereby certify that the foregoing documents are being deposited with the United States Postal Service as First Class Mail, in an envelope addressed to Mail Stop PCT (DO/EO/US), Commissioner for Patents, P.O. Box 1450, Alexandria VA 22313-1450, on this date of March 19, 2007.


John Barretto

RESPONSE TO NOTIFICATION OF MISSING REQUIREMENTS

Mail Stop PCT (DO/EO/US)
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

This paper is being filed in response to the Notification of Missing Requirements Under 35 U.S.C. 371 in the United States Designated/Elected Office (DO/EO/US) mailed on September 19, 2006, in the above-referenced application.

Enclosed is a copy of the Notification of Missing Requirements Under 35 U.S.C. 371 in the United States Designated/Elected Office (DO/EO/US); a Petition for a Four-Month Extension of Time; a paper copy of the Sequence Listing; a Computer Readable Form of the Sequence Listing (CRF); a Statement to Support the Filing and Submission of the Sequence Listing in accordance with 37 CFR §§1.821-1.825; a Preliminary Amendment; Declaration signed by Inventors Wu and Hung; and Powers of Attorney signed by Inventors Wu and Hung.

Please charge the surcharge for a small entity (\$65.00) to our **Deposit Account No. 06-1448, Reference JHV-050.01**. A copy of this Response is enclosed.

Although we believe that we have submitted the correct amount to cover the above-listed items, the Commissioner is authorized to credit any overpayment or charge any deficiencies to our **Deposit Account No. 06-1448, Reference JHV-050.01.**

Respectfully Submitted,

Date: March 19, 2007


Customer No: 25181

Patent Group

Foley Hoag LLP

155 Seaport Blvd.

Boston, MA 02210-2600



Janann Y. Ali, Ph.D.
Reg. No. 54,958
Agent for Applicants
Tel. (617) 832-1000
Fax. (617) 832-7000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Wu, Tzyy-Choou *et al.*

Application No: 10/555,669

International Filing Date: May 5, 2004

For: ANTI-CANCER DNA VACCINE
EMPLOYING PLASMIDS ENCODING
SIGNAL SEQUENCE, MUTANT ONCO-
PROTEIN ANTIGEN, AND HEAT
SHOCK PROTEIN

Art Unit: *To be Determined*


Confirmation No.: 9879

Examiner: *To be Determined*

Docket No. JHV-050.01

CERTIFICATE OF FIRST CLASS MAILING

I hereby certify that the foregoing documents are being deposited with the United States Postal Service as First Class Mail, in an envelope addressed to Mail Stop PCT (DO/EO/US), Commissioner for Patents, P.O. Box 1450, Alexandria VA 22313-1450, on this date of March 19, 2007.


John Barretto

RESPONSE TO NOTIFICATION OF MISSING REQUIREMENTS

Mail Stop PCT (DO/EO/US)
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

This paper is being filed in response to the Notification of Missing Requirements Under 35 U.S.C. 371 in the United States Designated/Elected Office (DO/EO/US) mailed on September 19, 2006, in the above-referenced application.

Enclosed is a copy of the Notification of Missing Requirements Under 35 U.S.C. 371 in the United States Designated/Elected Office (DO/EO/US); a Petition for a Four-Month Extension of Time; a paper copy of the Sequence Listing; a Computer Readable Form of the Sequence Listing (CRF); a Statement to Support the Filing and Submission of the Sequence Listing in accordance with 37 CFR §§1.821-1.825; a Preliminary Amendment; Declaration signed by Inventors Wu and Hung; and Powers of Attorney signed by Inventors Wu and Hung.

Please charge the surcharge for a small entity (\$65.00) to our **Deposit Account No. 06-1448, Reference JHV-050.01**. A copy of this Response is enclosed.

Although we believe that we have submitted the correct amount to cover the above-listed items, the Commissioner is authorized to credit any overpayment or charge any deficiencies to our **Deposit Account No. 06-1448, Reference JHV-050.01.**

Respectfully Submitted,

Date: March 19, 2007


Customer No: 25181

Patent Group

Foley Hoag LLP

155 Seaport Blvd.

Boston, MA 02210-2600



Janann Y. Ali, Ph.D.

Reg. No. 54,958

Agent for Applicants

Tel. (617) 832-1000

Fax. (617) 832-7000



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
 www.uspto.gov

JHU-18

52L

mfr

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
10/555,669	Tzyy-Chouu Wu	26148.1180

INTERNATIONAL APPLICATION NO.

PCT/US04/13756

I.A. FILING DATE

PRIORITY DATE

05/05/2004

05/05/2003

McKenna Long & Aldridge
 1900 K Street NW
 Washington, DC 20006

Missing Requirement
DUE: *11/19/07-w/2 month*
FINAL: *4/19/07*

CONFIRMATION NO. 9879

371 FORMALITIES LETTER



OC00000020495147

Date Mailed: 09/19/2006

NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 U.S.C. 371 IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as a Designated / Elected Office (37 CFR 1.495).

- Indication of Small Entity Status
- Copy of the International Application filed on 11/07/2005
- Copy of the International Search Report filed on 11/07/2005
- Preliminary Amendments filed on 11/07/2005
- Information Disclosure Statements filed on 11/07/2005
- U.S. Basic National Fees filed on 11/07/2005
- Priority Documents filed on 11/07/2005

RECEIVED	
SEP 21 2006	
DOCKETED BY: <i>JM</i>	
DUE DATE: <i>11/19/06</i> / FINAL: <i>4/19/07</i>	
ATTORNEY CONFIRMATION:	
McKENNA LONG & ALDRIDGE	

The applicant needs to satisfy supplemental fees problems indicated below.

The following items **MUST** be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

- Oath or declaration of the inventors, in compliance with 37 CFR 1.497(a) and (b), identifying the application by the International application number and international filing date.
- To avoid abandonment, a surcharge (for late submission of filing fee, search fee, examination fee or oath or declaration) as set forth in 37 CFR 1.492(h) of \$65 for a small entity in compliance with 37 CFR 1.27, must be submitted with the missing items identified in this letter.

SUMMARY OF FEES DUE:

Total additional fees required for this application is **\$65** for a Small Entity:

- **\$65** Surcharge.

- This application clearly fails to comply with the requirements of 37 CFR. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", **as well as an amendment specifically directing its entry into the application.** Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patentin Software Program Help @ ebc@uspto.gov

ALL OF THE ITEMS SET FORTH ABOVE MUST BE SUBMITTED WITHIN TWO (2) MONTHS FROM THE DATE OF THIS NOTICE OR BY 32 MONTHS FROM THE PRIORITY DATE FOR THE APPLICATION, WHICHEVER IS LATER. FAILURE TO PROPERLY RESPOND WILL RESULT IN ABANDONMENT.

The time period set above may be extended by filing a petition and fee for extension of time under the provisions of 37 CFR 1.136(a).

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

*A copy of this notice **MUST** be returned with the response.*

JOHN L ANDERSON


Telephone: (703) 308-9140 EXT 211

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/555,669	PCT/US04/13756	26148.1180

FORM PCT/DO/EO/905 (371 Formalities Notice)

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.


PETITION FOR EXTENSION OF TIME UNDER 37 CFR 1.136(a) FY 2006 (Fees pursuant to the Consolidated Appropriations Act, 2005 (H.R. 4818).)		Docket Number (Optional) JHV-050.01																									
Application Number 10/555,669-Conf. #9879		Filed May 5, 2004																									
For ANTI-CANCER DNA VACCINE EMPLOYING PLASMIDS ENCODING SIGNAL SEQUENCE, MUTANT ONCO-PROTEIN ANTIGEN, AND HEAT SHOCK PROTEIN																											
Art Unit N/A		Examiner Not Yet Assigned																									
<p>This is a request under the provisions of 37 CFR 1.136(a) to extend the period for filing a reply in the above identified application.</p> <p>The requested extension and fee are as follows (check time period desired and enter the appropriate fee below):</p> <table style="width: 100%; border-collapse: collapse;"><thead><tr><th></th><th style="text-align: center;"><u>Fee</u></th><th colspan="2" style="text-align: center;"><u>Small Entity Fee</u></th></tr></thead><tbody><tr><td><input type="checkbox"/> One month (37 CFR 1.17(a)(1))</td><td style="text-align: center;">\$120</td><td style="text-align: center;">\$60</td><td style="text-align: center;">\$ _____</td></tr><tr><td><input type="checkbox"/> Two months (37 CFR 1.17(a)(2))</td><td style="text-align: center;">\$450</td><td style="text-align: center;">\$225</td><td style="text-align: center;">\$ _____</td></tr><tr><td><input type="checkbox"/> Three months (37 CFR 1.17(a)(3))</td><td style="text-align: center;">\$1020</td><td style="text-align: center;">\$510</td><td style="text-align: center;">\$ _____</td></tr><tr><td><input checked="" type="checkbox"/> Four months (37 CFR 1.17(a)(4))</td><td style="text-align: center;">\$1590</td><td style="text-align: center;">\$795</td><td style="text-align: center;">\$ 795.00</td></tr><tr><td><input type="checkbox"/> Five months (37 CFR 1.17(a)(5))</td><td style="text-align: center;">\$2160</td><td style="text-align: center;">\$1080</td><td style="text-align: center;">\$ _____</td></tr></tbody></table> <p><input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27.</p> <p><input type="checkbox"/> A check in the amount of the fee is enclosed.</p> <p><input type="checkbox"/> Payment by credit card. Form PTO-2038 is attached.</p> <p><input type="checkbox"/> The Director has already been authorized to charge fees in this application to a Deposit Account.</p> <p><input checked="" type="checkbox"/> The Director is hereby authorized to charge any fees which may be required, or credit any overpayment, to Deposit Account Number <u>06-1448,</u> <u>Ref: JHV-050.01</u> . I have enclosed a duplicate copy of this sheet.</p> <p>I am the <input type="checkbox"/> applicant/inventor.</p> <p><input type="checkbox"/> assignee of record of the entire interest. See 37 CFR 3.71. Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96).</p> <p><input checked="" type="checkbox"/> attorney or agent of record. Registration Number <u>54,958</u></p> <p><input type="checkbox"/> attorney or agent under 37 CFR 1.34. Registration number if acting under 37 CFR 1.34 _____</p> <div style="display: flex; justify-content: space-between; margin-top: 20px;"><div style="width: 45%; text-align: center;"> _____ Signature Janann Y. Ali _____ Typed or printed name</div><div style="width: 45%; text-align: center;"><u>March 19, 2007</u> _____ Date <u>(617) 832-1000</u> _____ Telephone Number</div></div> <p><small>NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below.</small></p> <p><input checked="" type="checkbox"/> Total of <u>2</u> forms are submitted.</p>					<u>Fee</u>	<u>Small Entity Fee</u>		<input type="checkbox"/> One month (37 CFR 1.17(a)(1))	\$120	\$60	\$ _____	<input type="checkbox"/> Two months (37 CFR 1.17(a)(2))	\$450	\$225	\$ _____	<input type="checkbox"/> Three months (37 CFR 1.17(a)(3))	\$1020	\$510	\$ _____	<input checked="" type="checkbox"/> Four months (37 CFR 1.17(a)(4))	\$1590	\$795	\$ 795.00	<input type="checkbox"/> Five months (37 CFR 1.17(a)(5))	\$2160	\$1080	\$ _____
	<u>Fee</u>	<u>Small Entity Fee</u>																									
<input type="checkbox"/> One month (37 CFR 1.17(a)(1))	\$120	\$60	\$ _____																								
<input type="checkbox"/> Two months (37 CFR 1.17(a)(2))	\$450	\$225	\$ _____																								
<input type="checkbox"/> Three months (37 CFR 1.17(a)(3))	\$1020	\$510	\$ _____																								
<input checked="" type="checkbox"/> Four months (37 CFR 1.17(a)(4))	\$1590	\$795	\$ 795.00																								
<input type="checkbox"/> Five months (37 CFR 1.17(a)(5))	\$2160	\$1080	\$ _____																								

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the U.S. Postal Service on the date shown below with sufficient postage as First Class Mail, in an envelope addressed to: Mail Stop PCT (DO/EO/US), Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: March 19, 2007

Signature:  (John Barretto)

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PETITION FOR EXTENSION OF TIME UNDER 37 CFR 1.136(a) FY 2006 (Fees pursuant to the Consolidated Appropriations Act, 2005 (H.R. 4818).)		Docket Number (Optional) JHV-050.01																									
Application Number 10/555,669-Conf. #9879		Filed May 5, 2004																									
For ANTI-CANCER DNA VACCINE EMPLOYING PLASMIDS ENCODING SIGNAL SEQUENCE, MUTANT ONCO-PROTEIN ANTIGEN, AND HEAT SHOCK PROTEIN																											
Art Unit N/A		Examiner Not Yet Assigned																									
<p>This is a request under the provisions of 37 CFR 1.136(a) to extend the period for filing a reply in the above identified application.</p> <p>The requested extension and fee are as follows (check time period desired and enter the appropriate fee below):</p> <table style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 40%;"></th> <th style="width: 15%; text-align: center;">Fee</th> <th style="width: 15%; text-align: center;">Small Entity Fee</th> <th style="width: 30%;"></th> </tr> </thead> <tbody> <tr> <td><input type="checkbox"/> One month (37 CFR 1.17(a)(1))</td> <td style="text-align: center;">\$120</td> <td style="text-align: center;">\$60</td> <td style="text-align: center;">\$ _____</td> </tr> <tr> <td><input type="checkbox"/> Two months (37 CFR 1.17(a)(2))</td> <td style="text-align: center;">\$450</td> <td style="text-align: center;">\$225</td> <td style="text-align: center;">\$ _____</td> </tr> <tr> <td><input type="checkbox"/> Three months (37 CFR 1.17(a)(3))</td> <td style="text-align: center;">\$1020</td> <td style="text-align: center;">\$510</td> <td style="text-align: center;">\$ _____</td> </tr> <tr> <td><input checked="" type="checkbox"/> Four months (37 CFR 1.17(a)(4))</td> <td style="text-align: center;">\$1590</td> <td style="text-align: center;">\$795</td> <td style="text-align: center;">\$ 795.00</td> </tr> <tr> <td><input type="checkbox"/> Five months (37 CFR 1.17(a)(5))</td> <td style="text-align: center;">\$2160</td> <td style="text-align: center;">\$1080</td> <td style="text-align: center;">\$ _____</td> </tr> </tbody> </table> <p><input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27.</p> <p><input type="checkbox"/> A check in the amount of the fee is enclosed.</p> <p><input type="checkbox"/> Payment by credit card. Form PTO-2038 is attached.</p> <p><input type="checkbox"/> The Director has already been authorized to charge fees in this application to a Deposit Account.</p> <p><input checked="" type="checkbox"/> The Director is hereby authorized to charge any fees which may be required, or credit any overpayment, to Deposit Account Number <u>06-1448,</u> Ref: JHV-050.01 . I have enclosed a duplicate copy of this sheet.</p> <p>I am the <input type="checkbox"/> applicant/inventor.</p> <p><input type="checkbox"/> assignee of record of the entire interest. See 37 CFR 3.71. Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96).</p> <p><input checked="" type="checkbox"/> attorney or agent of record. Registration Number <u>54,958</u></p> <p><input type="checkbox"/> attorney or agent under 37 CFR 1.34. Registration number if acting under 37 CFR 1.34 _____</p> <p style="text-align: center;">  _____ Signature </p> <p style="text-align: center;"> _____ Janann Y. Ali Typed or printed name </p> <p style="text-align: right;"> _____ March 19, 2007 Date </p> <p style="text-align: right;"> _____ (617) 832-1000 Telephone Number </p> <p>NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below.</p> <p><input checked="" type="checkbox"/> Total of <u>2</u> forms are submitted.</p>					Fee	Small Entity Fee		<input type="checkbox"/> One month (37 CFR 1.17(a)(1))	\$120	\$60	\$ _____	<input type="checkbox"/> Two months (37 CFR 1.17(a)(2))	\$450	\$225	\$ _____	<input type="checkbox"/> Three months (37 CFR 1.17(a)(3))	\$1020	\$510	\$ _____	<input checked="" type="checkbox"/> Four months (37 CFR 1.17(a)(4))	\$1590	\$795	\$ 795.00	<input type="checkbox"/> Five months (37 CFR 1.17(a)(5))	\$2160	\$1080	\$ _____
	Fee	Small Entity Fee																									
<input type="checkbox"/> One month (37 CFR 1.17(a)(1))	\$120	\$60	\$ _____																								
<input type="checkbox"/> Two months (37 CFR 1.17(a)(2))	\$450	\$225	\$ _____																								
<input type="checkbox"/> Three months (37 CFR 1.17(a)(3))	\$1020	\$510	\$ _____																								
<input checked="" type="checkbox"/> Four months (37 CFR 1.17(a)(4))	\$1590	\$795	\$ 795.00																								
<input type="checkbox"/> Five months (37 CFR 1.17(a)(5))	\$2160	\$1080	\$ _____																								

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the U.S. Postal Service on the date shown below with sufficient postage as First Class Mail, in an envelope addressed to: Mail Stop PCT (DO/EO/US), Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: March 19, 2007

Signature:  (John Barretto)

PC/MS-DOS PATENTIN 3.3
WU, TZZY-CHOU et al.
Appl. No.: 10/555,669
Filed: 05-MAY-2004
Data Rec: 15-FEB-2007
Atty. Dkt. No: JHV-050.01
(19546-5001)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Atty. Docket No: JHV-050.01 (19546-5001)

In re patent application of

WU, TZZY-CHOU et al.

Serial No. 10/555,669

Filed: May 5, 2004

For: ANTI-CANCER DNA VACCINE EMPLOYING PLASMIDS ENCODING SIGNAL SEQUENCE,
MUTANT ONCOPROTEIN ANTIGEN, AND HEAT SHOCK PROTEIN

STATEMENT TO SUPPORT FILING AND SUBMISSION IN
ACCORDANCE WITH 37 C.F.R. §§ 1.821-1.825

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450
Mail Stop SEQUENCE

Sir:

In connection with a Sequence Listing submitted concurrently
herewith, the undersigned hereby states that:

1. the submission, filed herewith in accordance with 37
C.F.R. § 1.821(g), does not include new matter;
2. the content of the attached paper copy and the
attached computer readable copy of the Sequence Listing, submitted in
accordance with 37 C.F.R. § 1.821(c) and (e), respectively, are the same.

Respectfully submitted,

Feb. 15, 2007
Date


James A. Coburn

HARBOR CONSULTING IP SERVICES, INC.
1500A Lafayette Road, #262
Portsmouth, N.H. 03801
800-318-3021

SEQUENCE LISTING

<110> WU, TZZY-CHOOU
HUNG, CHIEN, FU

<120> ANTI-CANCER DNA VACCINE EMPLOYING PLASMIDS ENCODING
SIGNAL SEQUENCE, MUTANT ONCOPROTEIN ANTIGEN, AND HEAT
SHOCK PROTEIN

<130> JHV-050.01 (19546-5001)

<140> 10/555,669

<141> 2004-05-05

<150> PCT/US04/013756

<151> 2004-05-05

<150> 60/467,602

<151> 2003-05-05

<160> 20

<170> PatentIn Ver. 3.3

<210> 1

<211> 297

<212> DNA

<213> Human papillomavirus

<220>

<221> CDS

<222> (1)..(297)

<400> 1

atg cat gga gat aca cct aca ttg cat gaa tat atg tta gat ttg caa	48
Met His Gly Asp Thr Pro Thr Leu His Glu Tyr Met Leu Asp Leu Gln	
1 5 10 15	

cca gag aca act gat ctc tac tgt tat gag caa tta aat gac agc tca	96
Pro Glu Thr Thr Asp Leu Tyr Cys Tyr Glu Gln Leu Asn Asp Ser Ser	
20 25 30	

gag gag gag gat gaa ata gat ggt cca gct gga caa gca gaa ccg gac	144
Glu Glu Glu Asp Glu Ile Asp Gly Pro Ala Gly Gln Ala Glu Pro Asp	
35 40 45	

aga gcc cat tac aat att gta acc ttt tgt tgc aag tgt gac tct acg	192
Arg Ala His Tyr Asn Ile Val Thr Phe Cys Cys Lys Cys Asp Ser Thr	
50 55 60	

ctt cgg ttg tgc gta caa agc aca cac gta gac att cgt act ttg gaa	240
Leu Arg Leu Cys Val Gln Ser Thr His Val Asp Ile Arg Thr Leu Glu	
65 70 75 80	

gac ctg tta atg ggc aca cta gga att gtg tgc ccc atc tgt tct cag	288
Asp Leu Leu Met Gly Thr Leu Gly Ile Val Cys Pro Ile Cys Ser Gln	
85 90 95	

gat aag ctt
Asp Lys Leu

297

<210> 2
<211> 99
<212> PRT
<213> Human papillomavirus

<400> 2
Met His Gly Asp Thr Pro Thr Leu His Glu Tyr Met Leu Asp Leu Gln
1 5 10 15
Pro Glu Thr Thr Asp Leu Tyr Cys Tyr Glu Gln Leu Asn Asp Ser Ser
20 25 30
Glu Glu Glu Asp Glu Ile Asp Gly Pro Ala Gly Gln Ala Glu Pro Asp
35 40 45
Arg Ala His Tyr Asn Ile Val Thr Phe Cys Cys Lys Cys Asp Ser Thr
50 55 60
Leu Arg Leu Cys Val Gln Ser Thr His Val Asp Ile Arg Thr Leu Glu
65 70 75 80
Asp Leu Leu Met Gly Thr Leu Gly Ile Val Cys Pro Ile Cys Ser Gln
85 90 95

Asp Lys Leu

<210> 3
<211> 98
<212> PRT
<213> Human papillomavirus

<400> 3
Met His Gly Asp Thr Pro Thr Leu His Glu Tyr Met Leu Asp Leu Gln
1 5 10 15
Pro Glu Thr Thr Asp Leu Tyr Cys Tyr Glu Gln Leu Asn Asp Ser Ser
20 25 30
Glu Glu Glu Asp Glu Ile Asp Gly Pro Ala Gly Gln Ala Glu Pro Asp
35 40 45
Arg Ala His Tyr Asn Ile Val Thr Phe Cys Cys Lys Cys Asp Ser Thr
50 55 60
Leu Arg Leu Cys Val Gln Ser Thr His Val Asp Ile Arg Thr Leu Glu
65 70 75 80
Asp Leu Leu Met Gly Thr Leu Gly Ile Val Cys Pro Ile Cys Ser Gln
85 90 95

Lys Pro

<210> 4
 <211> 158
 <212> PRT
 <213> Human papillomavirus

<400> 4

Met His Gln Lys Arg Thr Ala Met Phe Gln Asp Pro Gln Glu Arg Pro
 1 5 10 15

Arg Lys Leu Pro Gln Leu Cys Thr Glu Leu Gln Thr Thr Ile His Asp
 20 25 30

Ile Ile Leu Glu Cys Val Tyr Cys Lys Gln Gln Leu Leu Arg Arg Glu
 35 40 45

Val Tyr Asp Phe Ala Phe Arg Asp Leu Cys Ile Val Tyr Arg Asp Gly
 50 55 60

Asn Pro Tyr Ala Val Cys Asp Lys Cys Leu Lys Phe Tyr Ser Lys Ile
 65 70 75 80

Ser Glu Tyr Arg His Tyr Cys Tyr Ser Leu Tyr Gly Thr Thr Leu Glu
 85 90 95

Gln Gln Tyr Asn Lys Pro Leu Cys Asp Leu Leu Ile Arg Cys Ile Asn
 100 105 110

Cys Gln Lys Pro Leu Cys Pro Glu Glu Lys Gln Arg His Leu Asp Lys
 115 120 125

Lys Gln Arg Phe His Asn Ile Arg Gly Arg Trp Thr Gly Arg Cys Met
 130 135 140

Ser Cys Cys Arg Ser Ser Arg Thr Arg Arg Glu Thr Gln Leu
 145 150 155

<210> 5
 <211> 151
 <212> PRT
 <213> Human papillomavirus

<400> 5

Met Phe Gln Asp Pro Gln Glu Arg Pro Arg Lys Leu Pro Gln Leu Cys
 1 5 10 15

Thr Glu Leu Gln Thr Thr Ile His Asp Ile Ile Leu Glu Cys Val Tyr
 20 25 30

Cys Lys Gln Gln Leu Leu Arg Arg Glu Val Tyr Asp Phe Ala Phe Arg
 35 40 45

Asp Leu Cys Ile Val Tyr Arg Asp Gly Asn Pro Tyr Ala Val Cys Asp
 50 55 60

Lys Cys Leu Lys Phe Tyr Ser Lys Ile Ser Glu Tyr Arg His Tyr Cys
65 70 75 80

Tyr Ser Leu Tyr Gly Thr Thr Leu Glu Gln Gln Tyr Asn Lys Pro Leu
85 90 95

Cys Asp Leu Leu Ile Arg Cys Ile Asn Cys Gln Lys Pro Leu Cys Pro
100 105 110

Glu Glu Lys Gln Arg His Leu Asp Lys Lys Gln Arg Phe His Asn Ile
115 120 125

Arg Gly Arg Trp Thr Gly Arg Cys Met Ser Cys Cys Arg Ser Ser Arg
130 135 140

Thr Arg Arg Glu Thr Gln Leu
145 150

<210> 6

<211> 378

<212> DNA

<213> Human papillomavirus

<400> 6

atggcgcccc ccggcgcccc gggcgcgctg ctccctcctgc tgctggcagg ccttgacacat 60
ggcgccctcag cactctttga ggatctaatac atgcatggag atacacctac attgcatgaa 120
tatatgtag atttgcaacc agagacaact gatctctact gttatgagca attaaatgac 180
agctcagagg aggaggatga aatagatggt ccagctggac aagcagaacc ggacagagcc 240
cattacaata ttgtaacctt ttgttgcaag tgtgactcta cgcttcgggt gtgcgtacaa 300
agcacacacg tagacattcg tactttggaa gacctgttaa tgggcacact aggaattgtg 360
tgccccatct gttctcaa 378

<210> 7

<211> 127

<212> PRT

<213> Human papillomavirus

<400> 7

Met Ala Ala Pro Gly Ala Arg Arg Pro Leu Leu Leu Leu Leu Ala
1 5 10 15

Gly Leu Ala His Gly Ala Ser Ala Leu Phe Glu Asp Leu Ile Met His
20 25 30

Gly Asp Thr Pro Thr Leu His Glu Tyr Met Leu Asp Leu Gln Pro Glu
35 40 45

Thr Thr Asp Leu Tyr Cys Tyr Glu Gln Leu Asn Asp Ser Ser Glu Glu
50 55 60

Glu Asp Glu Ile Asp Gly Pro Ala Gly Gln Ala Glu Pro Asp Arg Ala
65 70 75 80

His Tyr Asn Ile Val Thr Phe Cys Cys Lys Cys Asp Ser Thr Leu Arg
85 90 95

Leu Cys Val Gln Ser Thr His Val Asp Ile Arg Thr Leu Glu Asp Leu
 100 105 110

Leu Met Gly Thr Leu Gly Ile Val Cys Pro Ile Cys Ser Gln Pro
 115 120 125

<210> 8
 <211> 90
 <212> DNA
 <213> Human papillomavirus

<400> 8
 atggcgcccc ccggcgcccc gcggcgcgctg ctctctgtgc tgctggcagg ccttgacacat 60
 ggcgccctcag cactctttga ggatctaatac 90

<210> 9
 <211> 1878
 <212> DNA
 <213> Mycobacterium tuberculosis

<400> 9
 atggctcgtg cggctcgggat cgacctcggg accaccaact ccgtcgtctc ggttctggaa 60
 ggtggcgacc cggctcgtcgt cgccaactcc gagggctcca ggaccacccc gtcaattgtc 120
 gcgttcgccc gcaacgggtga ggtgctggtc ggccagcccc ccaagaacca ggcagtgacc 180
 aacgtcgtat gcaccgtgct ctcgggtcaag cgacacatgg gcagcgactg gtccatagag 240
 attgacggca agaaatacac gcgcgccggag atcagcgccc gcattctgat gaagctgaag 300
 cgcgacgccc aggcctacct cggtagggac attaccgacg cggttatcac gacgcccgcc 360
 tacttcaatg acgcccagcg tcaggccacc aaggacgccc gccagatcgc cggcctcaac 420
 gtgctcggga tcgtcaacga gcgcaccgcg gccgcgctgg cctacggcct cgacaagggc 480
 gagaaggagc agcgaatcct ggtcttcgac ttgggtgggtg gcactttcga cgtttccctg 540
 ctggagatcg gcgagggtgt ggttgaggtc cgtgccactt cgggtgacaa ccacctcggc 600
 ggcgacgact gggaccagcg ggtcgtcgat tggctgggtg acaagttcaa gggcaccagc 660
 ggcatcgatc tgaccaaggga caagatggcg atgcagcggc tgcgggaagc cgccgagaag 720
 gcaaagatcg agctgagttc gagtcagtc acctcgatca acctgcccta catcacgtc 780
 gacgccgaca agaaccggtt gttcttagac gagcagctga cccgcgcgga gttccaacgg 840
 atcactcagg acctgctgga ccgcactcgc aagccgttcc agtcggtgat cgctgacacc 900
 ggcatttcgg tgctcgagat cgatcacgtt gtgctcgtgg gtggttcgac ccggatgccc 960
 gcggtgaccg atctgggtcaa ggaactcacc ggccgcaagg aacccaacaa gggcgtcaac 1020
 cccgatgagg ttgtcgcggt gggagccgct ctgcaggccg gcgtcctcaa gggcgagggtg 1080
 aaagacgttc tgctgcttga tgttaccgcc ctgagcctgg gtatcgagac caaggcgagg 1140
 gtgatgacca ggctcatcga gcgcaacacc acgatcccca ccaagcggtc ggagactttc 1200
 accaccgccc acgacaacca accgtcgggtg cagatccagg tctatcaggg ggagcgtgag 1260
 atcgccgctc acaacaagtt gctcgggtcc ttcgagctga ccggcatccc gccggcgccc 1320
 cgggggattc cgcagatcga ggtcactttc gacatcgacg ccaacggcat tgtgcacgtc 1380
 accgccaagg acaagggcac cggcaaggag aacacgatcc gaatccagga aggctcgggc 1440
 ctgtccaagg aagacattga ccgcatgatc aaggacgccc aagcgcacgc cgaggaggat 1500
 cgcaagcgtc gcgaggaggc cgatgttcgt aatcaagccg agacattggt ctaccagacg 1560
 gagaagttcg tcaaagaaca gcgtgaggcc gaggggtggt cgaaggtacc tgaagacacg 1620
 ctgaacaagg ttgatgccgc ggtggcggaa gcgaaggcgg cacttgccgg atcgatattt 1680
 tcggccatca agtcggcgat ggagaagctg ggcaggagt cgcaggctct ggggcaagcg 1740
 atctacgaag cagctcaggc tgcgtcacag gccactggcg ctgcccaccc cggcgccgag 1800
 ccggcggtg cccaccccg ctcggtgat gacgttgtgg acgcggagggt ggtcgacgac 1860
 ggccgggagg ccaagtga 1878

<210> 10

<211> 625

<212> PRT

<213> Mycobacterium tuberculosis

<400> 10

Met Ala Arg Ala Val Gly Ile Asp Leu Gly Thr Thr Asn Ser Val Val
 1 5 10 15

Ser Val Leu Glu Gly Gly Asp Pro Val Val Val Ala Asn Ser Glu Gly
 20 25 30

Ser Arg Thr Thr Pro Ser Ile Val Ala Phe Ala Arg Asn Gly Glu Val
 35 40 45

Leu Val Gly Gln Pro Ala Lys Asn Gln Ala Val Thr Asn Val Asp Arg
 50 55 60

Thr Val Arg Ser Val Lys Arg His Met Gly Ser Asp Trp Ser Ile Glu
 65 70 75 80

Ile Asp Gly Lys Lys Tyr Thr Ala Pro Glu Ile Ser Ala Arg Ile Leu
 85 90 95

Met Lys Leu Lys Arg Asp Ala Glu Ala Tyr Leu Gly Glu Asp Ile Thr
 100 105 110

Asp Ala Val Ile Thr Thr Pro Ala Tyr Phe Asn Asp Ala Gln Arg Gln
 115 120 125

Ala Thr Lys Asp Ala Gly Gln Ile Ala Gly Leu Asn Val Leu Arg Ile
 130 135 140

Val Asn Glu Pro Thr Ala Ala Ala Leu Ala Tyr Gly Leu Asp Lys Gly
 145 150 155 160

Glu Lys Glu Gln Arg Ile Leu Val Phe Asp Leu Gly Gly Gly Thr Phe
 165 170 175

Asp Val Ser Leu Leu Glu Ile Gly Glu Gly Val Val Glu Val Arg Ala
 180 185 190

Thr Ser Gly Asp Asn His Leu Gly Gly Asp Asp Trp Asp Gln Arg Val
 195 200 205

Val Asp Trp Leu Val Asp Lys Phe Lys Gly Thr Ser Gly Ile Asp Leu
 210 215 220

Thr Lys Asp Lys Met Ala Met Gln Arg Leu Arg Glu Ala Ala Glu Lys
 225 230 235 240

Ala Lys Ile Glu Leu Ser Ser Ser Gln Ser Thr Ser Ile Asn Leu Pro
 245 250 255

Tyr Ile Thr Val Asp Ala Asp Lys Asn Pro Leu Phe Leu Asp Glu Gln
 260 265 270

Leu Thr Arg Ala Glu Phe Gln Arg Ile Thr Gln Asp Leu Leu Asp Arg
 275 280 285
 Thr Arg Lys Pro Phe Gln Ser Val Ile Ala Asp Thr Gly Ile Ser Val
 290 295 300
 Ser Glu Ile Asp His Val Val Leu Val Gly Gly Ser Thr Arg Met Pro
 305 310 315 320
 Ala Val Thr Asp Leu Val Lys Glu Leu Thr Gly Gly Lys Glu Pro Asn
 325 330 335
 Lys Gly Val Asn Pro Asp Glu Val Val Ala Val Gly Ala Ala Leu Gln
 340 345 350
 Ala Gly Val Leu Lys Gly Glu Val Lys Asp Val Leu Leu Leu Asp Val
 355 360 365
 Thr Pro Leu Ser Leu Gly Ile Glu Thr Lys Gly Gly Val Met Thr Arg
 370 375 380
 Leu Ile Glu Arg Asn Thr Thr Ile Pro Thr Lys Arg Ser Glu Thr Phe
 385 390 395 400
 Thr Thr Ala Asp Asp Asn Gln Pro Ser Val Gln Ile Gln Val Tyr Gln
 405 410 415
 Gly Glu Arg Glu Ile Ala Ala His Asn Lys Leu Leu Gly Ser Phe Glu
 420 425 430
 Leu Thr Gly Ile Pro Pro Ala Pro Arg Gly Ile Pro Gln Ile Glu Val
 435 440 445
 Thr Phe Asp Ile Asp Ala Asn Gly Ile Val His Val Thr Ala Lys Asp
 450 455 460
 Lys Gly Thr Gly Lys Glu Asn Thr Ile Arg Ile Gln Glu Gly Ser Gly
 465 470 475 480
 Leu Ser Lys Glu Asp Ile Asp Arg Met Ile Lys Asp Ala Glu Ala His
 485 490 495
 Ala Glu Glu Asp Arg Lys Arg Arg Glu Glu Ala Asp Val Arg Asn Gln
 500 505 510
 Ala Glu Thr Leu Val Tyr Gln Thr Glu Lys Phe Val Lys Glu Gln Arg
 515 520 525
 Glu Ala Glu Gly Gly Ser Lys Val Pro Glu Asp Thr Leu Asn Lys Val
 530 535 540
 Asp Ala Ala Val Ala Glu Ala Lys Ala Ala Leu Gly Gly Ser Asp Ile
 545 550 555 560
 Ser Ala Ile Lys Ser Ala Met Glu Lys Leu Gly Gln Glu Ser Gln Ala
 565 570 575

Leu Gly Gln Ala Ile Tyr Glu Ala Ala Gln Ala Ala Ser Gln Ala Thr
580 585 590

Gly Ala Ala His Pro Gly Gly Glu Pro Gly Gly Ala His Pro Gly Ser
595 600 605

Ala Asp Asp Val Val Asp Ala Glu Val Val Asp Asp Gly Arg Glu Ala
610 615 620

Lys
625

<210> 11
<211> 2104
<212> DNA
<213> Artificial Sequence

<220>
<221> CDS
<222> (1)..(2103)

<220>
<223> Description of Artificial Sequence: Synthetic
construct

<400> 11
atg cat gga gat aca cct aca ttg cat gaa tat atg tta gat ttg caa 48
Met His Gly Asp Thr Pro Thr Leu His Glu Tyr Met Leu Asp Leu Gln
1 5 10 15
cca gag aca act gat ctc tac tgt tat gag caa tta aat gac agc tca 96
Pro Glu Thr Thr Asp Leu Tyr Cys Tyr Glu Gln Leu Asn Asp Ser Ser
20 25 30
gag gag gag gat gaa ata gat ggt cca gct gga caa gca gaa ccg gac 144
Glu Glu Glu Asp Glu Ile Asp Gly Pro Ala Gly Gln Ala Glu Pro Asp
35 40 45
aga gcc cat tac aat att gta acc ttt tgt tgc aag tgt gac tct acg 192
Arg Ala His Tyr Asn Ile Val Thr Phe Cys Cys Lys Cys Asp Ser Thr
50 55 60
ctt cgg ttg tgc gta caa agc aca cac gta gac att cgt act ttg gaa 240
Leu Arg Leu Cys Val Gln Ser Thr His Val Asp Ile Arg Thr Leu Glu
65 70 75 80
gac ctg tta atg ggc aca cta gga att gtg tgc ccc atc tgt tct caa 288
Asp Leu Leu Met Gly Thr Leu Gly Ile Val Cys Pro Ile Cys Ser Gln
85 90 95
gga tcc atg gct cgt gcg gtc ggg atc gac ctc ggg acc acc aac tcc 336
Gly Ser Met Ala Arg Ala Val Gly Ile Asp Leu Gly Thr Thr Asn Ser
100 105 110
gtc gtc tcg gtt ctg gaa ggt ggc gac ccg gtc gtc gtc gcc aac tcc 384
Val Val Ser Val Leu Glu Gly Gly Asp Pro Val Val Val Ala Asn Ser
115 120 125

gag ggc tcc agg acc acc ccg tca att gtc gcg ttc gcc cgc aac ggt	432
Glu Gly Ser Arg Thr Thr Pro Ser Ile Val Ala Phe Ala Arg Asn Gly	
130 135 140	
gag gtg ctg gtc ggc cag ccc gcc aag aac cag gca gtg acc aac gtc	480
Glu Val Leu Val Gly Gln Pro Ala Lys Asn Gln Ala Val Thr Asn Val	
145 150 155 160	
gat cgc acc gtg cgc tcg gtc aag cga cac atg ggc agc gac tgg tcc	528
Asp Arg Thr Val Arg Ser Val Lys Arg His Met Gly Ser Asp Trp Ser	
165 170 175	
ata gag att gac ggc aag aaa tac acc gcg ccg gag atc agc gcc cgc	576
Ile Glu Ile Asp Gly Lys Lys Tyr Thr Ala Pro Glu Ile Ser Ala Arg	
180 185 190	
att ctg atg aag ctg aag cgc gac gcc gag gcc tac ctc ggt gag gac	624
Ile Leu Met Lys Leu Lys Arg Asp Ala Glu Ala Tyr Leu Gly Glu Asp	
195 200 205	
att acc gac gcg gtt atc acg acg ccc gcc tac ttc aat gac gcc cag	672
Ile Thr Asp Ala Val Ile Thr Thr Pro Ala Tyr Phe Asn Asp Ala Gln	
210 215 220	
cgt cag gcc acc aag gac gcc ggc cag atc gcc ggc ctc aac gtg ctg	720
Arg Gln Ala Thr Lys Asp Ala Gly Gln Ile Ala Gly Leu Asn Val Leu	
225 230 235 240	
cgg atc gtc aac gag ccg acc gcg gcc gcg ctg gcc tac ggc ctc gac	768
Arg Ile Val Asn Glu Pro Thr Ala Ala Ala Leu Ala Tyr Gly Leu Asp	
245 250 255	
aag ggc gag aag gag cag cga atc ctg gtc ttc gac ttg ggt ggt ggc	816
Lys Gly Glu Lys Glu Gln Arg Ile Leu Val Phe Asp Leu Gly Gly Gly	
260 265 270	
act ttc gac gtt tcc ctg ctg gag atc ggc gag ggt gtg gtt gag gtc	864
Thr Phe Asp Val Ser Leu Leu Glu Ile Gly Glu Gly Val Val Glu Val	
275 280 285	
cgt gcc act tcg ggt gac aac cac ctc ggc ggc gac gac tgg gac cag	912
Arg Ala Thr Ser Gly Asp Asn His Leu Gly Gly Asp Asp Trp Asp Gln	
290 295 300	
cgg gtc gtc gat tgg ctg gtg gac aag ttc aag ggc acc agc ggc atc	960
Arg Val Val Asp Trp Leu Val Asp Lys Phe Lys Gly Thr Ser Gly Ile	
305 310 315 320	
gat ctg acc aag gac aag atg gcg atg cag ccg ctg ccg gaa gcc gcc	1008
Asp Leu Thr Lys Asp Lys Met Ala Met Gln Arg Leu Arg Glu Ala Ala	
325 330 335	
gag aag gca aag atc gag ctg agt tcg agt cag tcc acc tcg atc aac	1056
Glu Lys Ala Lys Ile Glu Leu Ser Ser Ser Gln Ser Thr Ser Ile Asn	
340 345 350	

ctg ccc tac atc acc gtc gac gcc gac aag aac ccg ttg ttc tta gac	1104
Leu Pro Tyr Ile Thr Val Asp Ala Asp Lys Asn Pro Leu Phe Leu Asp	
355 360 365	
gag cag ctg acc cgc gcg gag ttc caa cgg atc act cag gac ctg ctg	1152
Glu Gln Leu Thr Arg Ala Glu Phe Gln Arg Ile Thr Gln Asp Leu Leu	
370 375 380	
gac cgc act cgc aag ccg ttc cag tcg gtg atc gct gac acc ggc att	1200
Asp Arg Thr Arg Lys Pro Phe Gln Ser Val Ile Ala Asp Thr Gly Ile	
385 390 395 400	
tcg gtg tcg gag atc gat cac gtt gtg ctc gtg ggt ggt tcg acc cgg	1248
Ser Val Ser Glu Ile Asp His Val Val Leu Val Gly Gly Ser Thr Arg	
405 410 415	
atg ccc gcg gtg acc gat ctg gtc aag gaa ctc acc ggc ggc aag gaa	1296
Met Pro Ala Val Thr Asp Leu Val Lys Glu Leu Thr Gly Gly Lys Glu	
420 425 430	
ccc aac aag ggc gtc aac ccc gat gag gtt gtc gcg gtg gga gcc gct	1344
Pro Asn Lys Gly Val Asn Pro Asp Glu Val Val Ala Val Gly Ala Ala	
435 440 445	
ctg cag gcc ggc gtc ctc aag ggc gag gtg aaa gac gtt ctg ctg ctt	1392
Leu Gln Ala Gly Val Leu Lys Gly Glu Val Lys Asp Val Leu Leu Leu	
450 455 460	
gat gtt acc ccg ctg agc ctg ggt atc gag acc aag ggc ggc gtg atg	1440
Asp Val Thr Pro Leu Ser Leu Gly Ile Glu Thr Lys Gly Gly Val Met	
465 470 475 480	
acc agg ctc atc gag cgc aac acc acg atc ccc acc aag cgg tcg gag	1488
Thr Arg Leu Ile Glu Arg Asn Thr Thr Ile Pro Thr Lys Arg Ser Glu	
485 490 495	
act ttc acc acc gcc gac gac aac caa ccg tcg gtg cag atc cag gtc	1536
Thr Phe Thr Thr Ala Asp Asp Asn Gln Pro Ser Val Gln Ile Gln Val	
500 505 510	
tat cag ggg gag cgt gag atc gcc gcg cac aac aag ttg ctc ggg tcc	1584
Tyr Gln Gly Glu Arg Glu Ile Ala Ala His Asn Lys Leu Leu Gly Ser	
515 520 525	
ttc gag ctg acc ggc atc ccg ccg gcg ccg cgg ggg att ccg cag atc	1632
Phe Glu Leu Thr Gly Ile Pro Pro Ala Pro Arg Gly Ile Pro Gln Ile	
530 535 540	
gag gtc act ttc gac atc gac gcc aac ggc att gtg cac gtc acc gcc	1680
Glu Val Thr Phe Asp Ile Asp Ala Asn Gly Ile Val His Val Thr Ala	
545 550 555 560	
aag gac aag ggc acc ggc aag gag aac acg atc cga atc cag gaa ggc	1728
Lys Asp Lys Gly Thr Gly Lys Glu Asn Thr Ile Arg Ile Gln Glu Gly	
565 570 575	

Asp Leu Leu Met Gly Thr Leu Gly Ile Val Cys Pro Ile Cys Ser Gln
 85 90 95

Gly Ser Met Ala Arg Ala Val Gly Ile Asp Leu Gly Thr Thr Asn Ser
 100 105 110

Val Val Ser Val Leu Glu Gly Gly Asp Pro Val Val Val Ala Asn Ser
 115 120 125

Glu Gly Ser Arg Thr Thr Pro Ser Ile Val Ala Phe Ala Arg Asn Gly
 130 135 140

Glu Val Leu Val Gly Gln Pro Ala Lys Asn Gln Ala Val Thr Asn Val
 145 150 155 160

Asp Arg Thr Val Arg Ser Val Lys Arg His Met Gly Ser Asp Trp Ser
 165 170 175

Ile Glu Ile Asp Gly Lys Lys Tyr Thr Ala Pro Glu Ile Ser Ala Arg
 180 185 190

Ile Leu Met Lys Leu Lys Arg Asp Ala Glu Ala Tyr Leu Gly Glu Asp
 195 200 205

Ile Thr Asp Ala Val Ile Thr Thr Pro Ala Tyr Phe Asn Asp Ala Gln
 210 215 220

Arg Gln Ala Thr Lys Asp Ala Gly Gln Ile Ala Gly Leu Asn Val Leu
 225 230 235 240

Arg Ile Val Asn Glu Pro Thr Ala Ala Ala Leu Ala Tyr Gly Leu Asp
 245 250 255

Lys Gly Glu Lys Glu Gln Arg Ile Leu Val Phe Asp Leu Gly Gly Gly
 260 265 270

Thr Phe Asp Val Ser Leu Leu Glu Ile Gly Glu Gly Val Val Glu Val
 275 280 285

Arg Ala Thr Ser Gly Asp Asn His Leu Gly Gly Asp Asp Trp Asp Gln
 290 295 300

Arg Val Val Asp Trp Leu Val Asp Lys Phe Lys Gly Thr Ser Gly Ile
 305 310 315 320

Asp Leu Thr Lys Asp Lys Met Ala Met Gln Arg Leu Arg Glu Ala Ala
 325 330 335

Glu Lys Ala Lys Ile Glu Leu Ser Ser Ser Gln Ser Thr Ser Ile Asn
 340 345 350

Leu Pro Tyr Ile Thr Val Asp Ala Asp Lys Asn Pro Leu Phe Leu Asp
 355 360 365

Glu Gln Leu Thr Arg Ala Glu Phe Gln Arg Ile Thr Gln Asp Leu Leu
 370 375 380

Asp Arg Thr Arg Lys Pro Phe Gln Ser Val Ile Ala Asp Thr Gly Ile
 385 390 395 400
 Ser Val Ser Glu Ile Asp His Val Val Leu Val Gly Gly Ser Thr Arg
 405 410 415
 Met Pro Ala Val Thr Asp Leu Val Lys Glu Leu Thr Gly Gly Lys Glu
 420 425 430
 Pro Asn Lys Gly Val Asn Pro Asp Glu Val Val Ala Val Gly Ala Ala
 435 440 445
 Leu Gln Ala Gly Val Leu Lys Gly Glu Val Lys Asp Val Leu Leu Leu
 450 455 460
 Asp Val Thr Pro Leu Ser Leu Gly Ile Glu Thr Lys Gly Gly Val Met
 465 470 475 480
 Thr Arg Leu Ile Glu Arg Asn Thr Thr Ile Pro Thr Lys Arg Ser Glu
 485 490 495
 Thr Phe Thr Thr Ala Asp Asp Asn Gln Pro Ser Val Gln Ile Gln Val
 500 505 510
 Tyr Gln Gly Glu Arg Glu Ile Ala Ala His Asn Lys Leu Leu Gly Ser
 515 520 525
 Phe Glu Leu Thr Gly Ile Pro Pro Ala Pro Arg Gly Ile Pro Gln Ile
 530 535 540
 Glu Val Thr Phe Asp Ile Asp Ala Asn Gly Ile Val His Val Thr Ala
 545 550 555 560
 Lys Asp Lys Gly Thr Gly Lys Glu Asn Thr Ile Arg Ile Gln Glu Gly
 565 570 575
 Ser Gly Leu Ser Lys Glu Asp Ile Asp Arg Met Ile Lys Asp Ala Glu
 580 585 590
 Ala His Ala Glu Glu Asp Arg Lys Arg Arg Glu Glu Ala Asp Val Arg
 595 600 605
 Asn Gln Ala Glu Thr Leu Val Tyr Gln Thr Glu Lys Phe Val Lys Glu
 610 615 620
 Gln Arg Glu Ala Glu Gly Gly Ser Lys Val Pro Glu Asp Thr Leu Asn
 625 630 635 640
 Lys Val Asp Ala Ala Val Ala Glu Ala Lys Ala Ala Leu Gly Gly Ser
 645 650 655
 Asp Ile Ser Ala Ile Lys Ser Ala Met Glu Lys Leu Gly Gln Glu Ser
 660 665 670
 Gln Ala Leu Gly Gln Ala Ile Tyr Glu Ala Ala Gln Ala Ala Ser Gln
 675 680 685

Ala Thr Gly Ala Ala His Pro Gly Ser Ala Asp Glu Ser
690 695 700

<210> 13

<211> 6681

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
vector

<400> 13

```

gctccgcccc cctgacgagc atcacaaaaa tgcagcgtca agtcagaggt ggcgaaaccc 60
gacaggacta taaagatacc aggcgtttcc cccctggaagc tccctcgtgc gctctcctgt 120
tccgaccctg ccgcttaccg gatacctgtc cgcctttctc ccttcgggaa gcgtggcgct 180
ttctcatagc tcacgctgta ggtatctcag ttcgggtgtag gtcgttcgct ccaagctggg 240
ctgtgtgcac gaaccccccg ttcagcccgga ccgctgcgcc ttatccggta actatcgtct 300
tgagtccaac ccggttaagac acgacttatc gccactggca gcagccactg gtaacaggat 360
tagcagagcg aggtatgtag gcggtgtac agagttcctg aagtgggtggc ctaactacgg 420
ctacactaga agaacagtat ttggtatctg cgctctgctg aagccagtta ccttcggaaa 480
aagagttggt agctcttgat ccggcaaaaca aaccaccgct ggtagcgggt gtttttttgt 540
ttgcaagcag cagattacgc gcagaaaaaa aggatctcaa gaagatcctt tgatcttttc 600
tacgggggtc gacgctcagt ggaacgaaaa ctcacgttaa gggatttttg tcatgagatt 660
atcaaaaagg atcttcacct agatcctttt aaattaaaaa tgaagtttta aatcaatcta 720
aagtatatat gagtaaaactt ggtctgacag ttaccaatgc ttaatcagtg aggcacctat 780
ctcagcgatc tgtctatttc gttcatccat agttgcctga ctcggggggg gggggcgctg 840
aggtctgcct cgtgaagaag gtgttgctga ctcataccag ggcaacgctt ttgccattgc 900
tacaggcatc gtggtgtcac gctcgtcgtt tgggtatggc tcattcagct ccggttccca 960
acgatcaagg cgagttacat gatcccccat gttgtgcaaa aaagcgggta gtccttcggt 1020
tccctcgatc gttgtcgaaa gtaagtggc cgcagtgtta tcaactcatg ttatggcagc 1080
actgcataat tctcttactg tcatgccatc cgtaagatgc tttctgtga ctggtgagta 1140
ctcaaccaag tcattctgag aatagtgtat ggcggcagcg agttgctctt gcccgcgctc 1200
aatacgggat aataccgcgc cacatagcag aactttaaaa gtgctcatca ttggaaaacg 1260
ttcttcgggg cgaaaactct caaggatctt accgctgttg agatccagtt cgatgtaacc 1320
cactcgtgca cctgaatcgc cccatcatcc agccagaaag tgagggagcc acggttgatg 1380
agagctttgt tgtaggtgga ccagttggtg attttgaact tttgctttgc cacggaacgg 1440
tctgcgttgt cgggaagatg cgtgatctga tccctcaact cagcaaaagt tcgatttatt 1500
caacaaagcc gccgtcccgt caagtcagcg taatgctctg ccagtgttac aaccaattaa 1560
ccaattctga ttagaaaaac tcatcgagca tcaaataaaa ctgcaattta ttcatacag 1620
gattatcaat accatatatt tgaaaaagcc gtttctgtaa tgaaggagaa aactcaccga 1680
ggcagttcca taggatggca agatcctggt atcggctcgc gattccgact cgtccaacat 1740
caatacaacc tatataattt ccctcgtcaa aaataagggt atcaagtgag aaatcaccat 1800
gagtgcgcac tgaatccggt gagaatggca aaagcttatg catttctttc cagacttggt 1860
caacaggcca gccattacgc tcgtcatcaa aatcactcgc atcaaccaa ccgttattca 1920
ttcgtgattg cgcctgagcg agacgaaata cgcgatcgct gttaaaagga caattacaaa 1980
caggaatcga atgcaaccgg cgcaggaaca ctgccagcgc atcaacaata ttttcacctg 2040
aatcaggata ttcttctaata acctggaatg ctgttttccc ggggatcgca gtggtgagta 2100
accatgcac atcaggagta cggataaaat gcttgatggt cggaagaggc ataaattccg 2160
tcagccagtt tagtctgacc atctcatctg taacatcatt ggcaacgcta cctttgccat 2220
gtttcagaaa caactctggc gcatcgggct tcccatataa tcgatagatt gtcgcacctg 2280
attgcccgac attatcgaga gccattttat acccatataa atcagcatcc atgttggaat 2340
ttaatcgcg cctcgagcaa gacgtttccc gttgaatatg gtcataaca ccccttgat 2400
tactgtttat gtaagcagac agttttattg ttcatgatga tataatttta tcttggtgaa 2460
tgtaacatca gagattttga gacacaacgt ggctttcccc cccccccat tattgaagca 2520
tttatcaggg ttattgtctc atgagcggat acatatattga atgtatttag aaaaataaac 2580

```

aaataggggt	tccgcgcaca	tttccccgaa	aagtgccacc	tgacgtctaa	gaaaccatta	2640
ttatcatgac	attaacctat	aaaaataggg	gtatcacgag	gccctttcgt	ctcgcgcggt	2700
tcgggtgatga	cgggtgaaaac	ctctgacaca	tgacagctccc	ggagacggtc	acagcttgct	2760
tgtaagcggg	tgccggggagc	agacaagccc	gtcagggcgc	gtcagcgggt	ggtggcgggt	2820
gtcggggctg	gcttaactat	gcggcatcag	agcagattgt	actgagagtg	caccatattg	2880
gggtgtgaaat	accgcacaga	tgcgtaagga	gaaaataaccg	catcagattg	gctattggcc	2940
attgcatacg	ttgtatccat	atcataatat	gtacatttat	attggctcat	gtccaacatt	3000
accgccatgt	tgacattgat	tattgactag	ttattaatag	taatcaatta	cggggctcatt	3060
agttcatgac	ccatatatgg	agttccgcgt	tacataactt	acggtaaatg	gcccgcctgg	3120
ctgaccgccc	aacgaccccc	gccatttgac	gtcaataatg	acgtatgttc	ccatagtaac	3180
gccaataggg	actttccatt	gacgtcaatg	gggtggagtat	ttacggtaaa	ctgcccactt	3240
ggcagtagac	caagtgtatc	atatgccaa	tacgccccct	attgacgtca	atgacggtaa	3300
atggccccgc	tggcattatg	cccagtagac	gaccttatgg	gactttccta	cttggcagta	3360
catctacgta	ttagtcatcg	ctattacat	gggtgatgcgg	ttttggcagt	acatcaatgg	3420
gcgtggatag	cgggtttgact	cacggggatt	tccaagtctc	caccccattg	acgtcaatgg	3480
gagtttgttt	tggcaccaaaa	atcaacggga	ctttccaaaa	tgctgtaaca	actccgcccc	3540
attgacgcaa	atgggcggta	ggcgtgtacg	gtgggaggtc	tatataagca	gagctcggtt	3600
agtgaaccgt	cagatcgccct	ggagacgcca	tccacgctgt	tttgacctcc	atagaagaca	3660
ccgggaccga	tccagccctcc	gcggccggga	acgggtgcatt	ggaacgcgga	ttccccgtgc	3720
caagagtgc	gtaagtaccg	cctatagact	ctataggcac	acccctttgg	ctcttatgca	3780
tgctatactg	tttttggcct	ggggcctata	cacccccgct	tccttatgct	ataggtgatg	3840
gtatagctta	gcctataggt	gtgggttatt	gaccattatt	gaccactcca	acggtggagg	3900
gcagtgtagt	ctgagcagta	ctcgttgctg	ccgcgcgcgc	caccagacat	aatagctgac	3960
agactaacag	actgttcctt	tccatgggtc	ttttctgcag	tcaccgtcgt	cgacgggtatc	4020
gataagcttg	atatcgaatt	cctcgacgga	ctctatggcg	gcccccgccg	ccggcgccgc	4080
gctgctcctg	ctgctgctgg	caggccttgc	acatggcgcc	tcagcactct	ttgaggatct	4140
aatcatgcat	ggagatacac	ctacattgca	tgaatatatg	ttagatttgc	aaccagagac	4200
aactgatctc	tacgggttatg	ggcaattaaa	tgacagctca	gaggaggagg	atgaaataga	4260
tggctccagct	ggacaagcag	aaccggacag	agcccattac	aatattgtaa	ccttttggtg	4320
caagtgtgac	tctacgcttc	ggttgtgcgt	acaaagcaca	cacgtagaca	ttcgtacttt	4380
ggaagacctg	ttaatgggca	cactaggaat	tgtgtgcccc	atctgttctc	aaggatccat	4440
ggctcgtgcg	gtcgggatcg	acctcgggac	caccaactcc	gtcgtctcgg	ttctggaagg	4500
tggcgacccg	gtcgtcgtcg	ccaactccga	gggctccagg	accaaccctg	caattgtcgc	4560
gttcgccccg	aacggtgagg	tgctggctcg	ccagccccgc	aagaaccagg	cggtagacca	4620
cgctgatcgc	accgtgcgct	cgggtcaagcg	acacatgggc	agcgaactgg	ccatagagat	4680
tgacgggcaag	aaatacacccg	cgccggagat	cagcgccccg	attctgatga	agctgaagcg	4740
cgacgcgcgag	gcctacctcg	gtgaggacat	taccgacgcg	gttatcacga	cgcccgccta	4800
cttcaatgac	gccagcgtc	aggccaccaa	ggacgcgggc	cagatcgccg	gcctcaacgt	4860
gctgcggatc	gtcaacgagc	cgaccgcggc	cgcgctggcc	tacggcctcg	acaaggcgga	4920
gaaggagcag	cgaatcctgg	tcttcgactt	gggtggtggc	actttcgacg	tttccctgct	4980
ggagatcggc	gaggggtgtg	ttgaggtccg	tgccacttcg	ggtgacaacc	acctcggcgg	5040
cgacgactgg	gaccagcggg	tcgtcgattg	gctggtggac	aagttcaagg	gcaccagcgg	5100
catcgatctg	accaaggaca	agatggcgat	gcagcggctg	cgggaagccg	ccgagaaggc	5160
aaagatcgag	ctgagttcga	gtcagttcac	ctcgatcaac	ctgcccctaca	tcaccgtcga	5220
cgcgcgacaag	aaccctgtgt	tcttagacga	gcagctgacc	cgcgcggagt	tccaacggat	5280
cactcaggac	ctgctggacc	gcactcgcaa	gccgttccag	tcggtgatcg	ctgacaccgg	5340
catttcgggtg	tcggagatcg	atcacgttgt	gctcgtgggt	ggttcgaccc	ggatgcccgc	5400
ggtgaccgat	ctggtcaagg	aactcaccgg	cggcaaggaa	cccaacaagg	gcgtcaaccc	5460
cgatgaggtt	gtcgcggtgg	gagccgctct	gcaggccggc	gtcctcaagg	gcgagggtgaa	5520
agacgttctg	ctgcttgatg	ttaccccgt	gagcctgggt	atcgagacca	agggcggggt	5580
gatgaccagg	ctcatcgagc	gcaacaccac	gatccccacc	aagcgttcgg	agactttcac	5640
caccgcccag	gacaaccaac	cgtcgggtgca	gatccaggtc	tatcaggggg	agcgtgagat	5700
cgccgcgcac	aacaagttgc	tcgggtcctt	cgagctgacc	ggcatcccgc	cggcgcccg	5760
ggggattccg	cgatcgagg	tcaactttcga	catcgacgcc	aacggcattg	tgacgtcac	5820
cgccaaggac	aagggcaccg	gcaaggagaa	cacgatccga	atccagggaag	gctcgggcct	5880
gtccaaggaa	gacattgacc	gcatgatcaa	ggacgcogaa	gcgcacgcgc	aggaggatcg	5940
caagcgtcgc	gaggaggccg	atgttcgtaa	tcaagccgag	acattgggtc	accagacgga	6000
gaagttcgtc	aaagaacagc	gtgaggccga	gggtgggttcg	aaggtacctg	aagacacgct	6060

```

gaacaagggt gatgccgagg tggcggaagc gaaggcggca cttggcggtat cggatatttc 6120
ggccatcaag tcggcgatgg agaagctggg ccaggagtcg caggctctgg ggcaagcgat 6180
ctacgaagca gctcaggctg cgtcacaggc cactggcgct gccaccccg gctcggctga 6240
tgaaagctta agtttaaacc gctagcctag agcggccgag gatccagatc tttttccctc 6300
tgccaaaaat tatggggaca tcatgaagcc ccttgagcat ctgacttctg gctaataaag 6360
gaaatttatt ttcattgcaa tagtgtgttg gaattttttg tgtctctcac tcggaaggac 6420
atatgggagg gcaaattcatt taaaacatca gaatgagtat ttggtttaga gtttggcaac 6480
atatgcccac tcttcgctt cctcgcacac tgactcgctg cgcgcggtcg ttcggtgagc 6540
gcgagcggta tcagtcact caaaggcggg aatacgggta tccacagaat caggggataa 6600
cgaggaagaa aacatgtgag caaaaggcca gcaaaaggcc aggaaccgta aaaaggccgc 6660
gttgctggcg tttttccata g                                     6681

```

```

<210> 14
<211> 37
<212> DNA
<213> Artificial Sequence

```

```

<220>
<223> Description of Artificial Sequence: Synthetic
      primer

```

```

<400> 14
ctgatctcta cggttatggg caattaaatg acagctc                                     37

```

```

<210> 15
<211> 36
<212> DNA
<213> Artificial Sequence

```

```

<220>
<223> Description of Artificial Sequence: Synthetic
      primer

```

```

<400> 15
gagctgtcat ttaattgccc ataaccgtag agatca                                     36

```

```

<210> 16
<211> 9
<212> PRT
<213> Human papillomavirus

```

```

<400> 16
Arg Ala His Tyr Asn Ile Val Thr Phe
 1               5

```

```

<210> 17
<211> 21
<212> DNA
<213> Artificial Sequence

```

```

<220>
<221> CDS
<222> (1)..(21)

```

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 17

ctc tac tgt tat gag caa tta
Leu Tyr Cys Tyr Glu Gln Leu

1

5

21

<210> 18

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
peptide

<400> 18

Leu Tyr Cys Tyr Glu Gln Leu

1

5

<210> 19

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<221> CDS

<222> (1)..(21)

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 19

ctc tac ggt tat ggg caa tta
Leu Tyr Gly Tyr Gly Gln Leu

1

5

21

<210> 20

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
peptide

<400> 20

Leu Tyr Gly Tyr Gly Gln Leu

1

5

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Wu, Tzyy-Chouu *et al.*

Application No: 10/555,669

International Filing Date: May 5, 2004

For: ANTI-CANCER DNA VACCINE
EMPLOYING PLASMIDS ENCODING
SIGNAL SEQUENCE, MUTANT ONCO-
PROTEIN ANTIGEN, AND HEAT
SHOCK PROTEIN

Art Unit: *To be Determined*


Confirmation No.: 9879

Examiner: *To be Determined*

Docket No. JHV-050.01

CERTIFICATE OF FIRST CLASS MAILING

I hereby certify that the foregoing documents are being deposited with the United States Postal Service as First Class Mail, in an envelope addressed to Mail Stop PCT (DO/EO/US), Commissioner for Patents, P.O. Box 1450, Alexandria VA 22313-1450, on this date of March 19, 2007.


John Barretto

PRELIMINARY AMENDMENT

Mail Stop PCT (DO/EO/US)
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir/Madam:

Prior to substantive examination of the above-referenced patent application, please amend the application as follows:

Amendments to the specification begin on page 2 of this paper.

Remarks begin on page 3 of this paper.

AMENDMENTS TO THE SPECIFICATION

Please replace the paragraph beginning on page 8, line 13 with the following amended paragraph:

Figure 5A is a schematic diagram of the pNGVL4a-Sig/E7 (detox) /HSP70 plasmid vector used for anti-tumor vaccination. ~~Indicated are various inserts and p~~ Fig. 5B discloses SEQ ID NOs: 17-20, respectively, in order of appearance.

Please replace the paragraph beginning on page 34, line 6 with the following amended paragraph:

A portion of SEQ ID NO: 13 ~~above vector showing by annotation~~annotated with the Sig, E7 (detox) and HSP-70 regions is shown below (nucleotides 3951-6350 of SEQ ID NO: 13). The vector sequence is in lower case; the signal peptide (Sig) is bold italic and annotated over the lines. The E7 (detox) sequence is upper case underscored (and annotated over the lines). The HSP70 sequence is italicized and underscored[[.]] (not bolded) and is also annotated over the lines.

REMARKS


The foregoing amendments have been made to correct typographical errors and to insert the required SEQ ID NO identifiers associated with various listed sequences. No new matter has been added.

CONCLUSION

Applicants respectfully request entry of the present Preliminary Amendment. Early and favorable consideration of the application is respectfully solicited. The Examiner may address any questions raised by this submission to the undersigned at (617) 832-1000. The Commissioner is hereby authorized to charge any necessary fees to our **Deposit Order Account No. 06-1448, reference JHV-050.01.**

Respectfully submitted,
FOLEY HOAG

Dated: March 19, 2007
Customer Number 25181
Patent Group
Foley Hoag LLP
155 Seaport Blvd.
Boston, MA 02210-2600
Tel: (617) 832-1000
FAX: (617) 832-7000


Janann Y. Ali, Ph.D.
Reg. No. 54,958
Agent for Applicant

**DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN
APPLICATION DATA SHEET (37 CFR 1.76)**

Title of Invention	ANTI-CANCER DNA VACCINE EMPLOYING PLASMIDS ENCODING SIGNAL SEQUENCE, MUTANT ONCOPROTEIN ANTIGEN, AND HEAT SHOCK PROTEIN
---------------------------	---

As the below named inventor(s), I/we declare that:

This declaration is directed to:

☐ The attached application, or
☒ Application No. PCT/US04/13756, filed on 05/05/2004,
☒ as amended on 11/07/2005 (if applicable);

I/we believe that I/we am/are the original and first inventor(s) of the subject matter which is claimed and for which a patent is sought;

I/we have reviewed and understand the contents of the above-identified application, including the claims, as amended by any amendment specifically referred to above;

I/we acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application.


WARNING:

Petitioner/applicant is cautioned to avoid submitting personal information in documents filed in a patent application that may contribute to identity theft. Personal information such as social security numbers, bank account numbers, or credit card numbers (other than a check or credit card authorization form PTO-2038 submitted for payment purposes) is never required by the USPTO to support a petition or an application. If this type of personal information is included in documents submitted to the USPTO, petitioners/applicants should consider redacting such personal information from the documents before submitting them to the USPTO. Petitioner/applicant is advised that the record of a patent application is available to the public after publication of the application (unless a non-publication request in compliance with 37 CFR 1.213(a) is made in the application) or issuance of a patent. Furthermore, the record from an abandoned application may also be available to the public if the application is referenced in a published application or an issued patent (see 37 CFR 1.14). Checks and credit card authorization forms PTO-2038 submitted for payment purposes are not retained in the application file and therefore are not publicly available.

All statements made herein of my/our own knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon.

FULL NAME OF INVENTOR(S)

Inventor one: Tzyy-Choou Wu

Signature:  Citizen of: U.S.A.

Inventor two: Chien-Fu Hung

Signature:  Citizen of: Taiwan

Inventor three: _____

Signature: _____ Citizen of: _____

Inventor four: _____

Signature: _____ Citizen of: _____

☐ Additional inventors or a legal representative are being named on _____ additional form(s) attached hereto.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

POWER OF ATTORNEY and CORRESPONDENCE ADDRESS INDICATION FORM	Application Number		10/555,669-Conf. #9879
	Filing Date		May 5, 2004
	First Named Inventor		Tzyy-Choo Wu
	Title	ANTI-CANCER DNA VACCINE EMPLOYING PLASMIDS ENCODING SIGNAL SEQUENCE, MUTANT ONCO-PROTEIN ANTIGEN, AND HEAT SHOCK PROTEIN	
	Art Unit		N/A
	Examiner Name		Not Yet Assigned
Attorney Docket No.		JHV-050.01	

I hereby revoke all previous powers of attorney given in the above-identified application.

I hereby appoint:

☒ Practitioners associated with the Customer Number: 25181

OR

☐ Practitioner(s) named below:

Name	Registration Number	Name	Registration Number

as my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith.

Please recognize or change the correspondence address for the above-identified application to:

☒ The address associated with the above-mentioned Customer Number:

OR

☐ The address associated with Customer Number:

OR

☐ Firm or Individual Name

Address

City

State

Zip

Country

Telephone

Email

I am the:

☒ Applicant/Inventor.

☐ Assignee of record of the entire interest. See 37 CFR 3.71.

Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96)

SIGNATURE of Applicant or Assignee of Record

Signature	<i>Tzyy-Choo Wu</i>	Date	2-21-07
Name	Tzyy-Choo Wu	Telephone	410-614-3899
Title and Company	Inventor		

NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below*.

☒ *Total of 2 forms are submitted.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

POWER OF ATTORNEY and CORRESPONDENCE ADDRESS INDICATION FORM	Application Number		10/555,669-Conf. #9879
	Filing Date		May 5, 2004
	First Named Inventor		Tzyy-Choo Wu
	Title	ANTI-CANCER DNA VACCINE EMPLOYING PLASMIDS ENCODING SIGNAL SEQUENCE, MUTANT ONCO-PROTEIN ANTIGEN, AND HEAT SHOCK PROTEIN	
	Art Unit		N/A
	Examiner Name		Not Yet Assigned
Attorney Docket No.		JHV-050.01	

I hereby revoke all previous powers of attorney given in the above-identified application.

I hereby appoint:

☒ Practitioners associated with the Customer Number:

OR

☐ Practitioner(s) named below:

Name	Registration Number	Name	Registration Number

as my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith.

Please recognize or change the correspondence address for the above-identified application to:

☒ The address associated with the above-mentioned Customer Number:

OR

☐ The address associated with Customer Number:

OR

☐ Firm or
Individual Name

Address

City

State

Zip

Country

Telephone


Email

I am the:

☒ Applicant/Inventor.

☐ Assignee of record of the entire interest. See 37 CFR 3.71.
Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96)

SIGNATURE of Applicant or Assignee of Record

Signature		Date	2/21/07
Name	Chien-Fu Hung	Telephone	410-502-8215
Title and Company	Inventor		

NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below*.

☒ *Total of 2 forms are submitted.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Wu, Tzyy-Choou *et al.*

Application No: 10/555,669

International Filing Date: May 5, 2004

For: ANTI-CANCER DNA VACCINE
EMPLOYING PLASMIDS ENCODING
SIGNAL SEQUENCE, MUTANT ONCO-
PROTEIN ANTIGEN, AND HEAT
SHOCK PROTEIN

Art Unit: *To be Determined*


Confirmation No.: 9879

Examiner: *To be Determined*

Docket No. JHV-050.01

CERTIFICATE OF FIRST CLASS MAILING

I hereby certify that the foregoing documents are being deposited with the United States Postal Service as First Class Mail, in an envelope addressed to Mail Stop PCT (DO/EO/US), Commissioner for Patents, P.O. Box 1450, Alexandria VA 22313-1450, on this date of March 19, 2007.


John Barretto

NOTIFICATION OF CHANGE OF ATTORNEY DOCKET NUMBER

Mail Stop PCT (DO/EO/US)
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The Attorney Docket Number of the above-identified patent application has changed. Please take notice that the *correct* Attorney Docket Number for this application should now be as follows:


JHV-050.01

Please reference **JHV-050.01** on all future correspondence to the attorney of record.

Respectfully Submitted,

Date: March 19, 2007

Customer No: 25181
Patent Group
Foley Hoag LLP
155 Seaport Blvd.
Boston, MA 02210-2600


Janann Y. Ali, Ph.D.
Reg. No. 54,958
Agent for Applicants
Tel. (617) 832-1000
Fax. (617) 832-7000